2024-02-13T00:00:00.000+11:00
Ongoing

103 Hummingbird

103 Hummingbird
Lung cancer

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/ - Cetuximab in Advanced Squamous Non-small Cell Lung Cancers

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/ - Cetuximab in Advanced Squamous Non-small Cell Lung Cancers

Trial overview

Topic

Lung cancer

Eligibility criteria

Inclusion criteria:

  • 18 Years and older
  • All genders
  • Locally advanced or metastatic squamous non-small cell lung cancer.
  • ECOG 0-1

Exclusion Criteria:

Prior treatment with HMBD-001, docetaxel, cetuximab or any other agent that targets Epidermal Growth Factor Receptor (EGFR) or HER3, including pan-HER inhibitors.

Study details

This is a phase 1b multi-center, open-label study of HMBD-001 in combination with docetaxel 
with or without cetuximab in participants with locally advanced or metastatic squamous 
Non-Small Cell Lung Cancers

Further information

Please click here for more information

Location
Northshore :::

Brisbane – ICON Cancer Clinic South Brisbane

Brisbane – ICON Cancer Clinic South Brisbane :::

Malvern – Cabrini Health

Malvern – Cabrini Health :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.